First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors

被引：43
|
作者：
Kopetz, S.
Mita, M. M.
Mok, I.
Sankhala, K. K.
Moseley, J.
Sherman, B. M.
Bradley, C. R.
Tolcher, A. W.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Canc Therapy & Res Ctr S Texas, San Antonio, TX 78229 USA
[3] BiPar Sci, Brisbane, CA USA
[4] S Texas Accelerated Res Therapeut, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.3577
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3577
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Recruitment experience in a phase 0 trial of ABT-888, an inhibitor of poly (ADP-ribose) polymerase (PARP), in patients (pts) with advanced malignancies
    Gutierrez, M.
    Kummar, S.
    Horneffer, Y.
    Juwara, L.
    Chen, A.
    Melillo, G.
    Pickeral, O.
    Tomaszewski, J. E.
    Murgo, A. J.
    Doroshow, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] Predictive Biomarkers for Immune Checkpoint Inhibitor (ICI) and Poly (ADP-Ribose) Polymerase (PARP) Inhibitor (PARPi) in Advanced Stage Breast Carcinoma
    Anderson, Sarah
    Bartow, Brooke
    Siegal, Gene
    Harada, Shuko
    Khoury, Katia
    Yalniz, Ceren
    Huo, Lei
    Ding, Qingqing
    Sahin, Aysegul
    Huang, Xiao
    LABORATORY INVESTIGATION, 2024, 104 (03) : S108 - S109
  • [33] The novel poly(ADP-ribose) polymerase (PARP)-1 Inhibitor, BSI-401, has antitumor activity and potentiates oxaliplatin cytotoxic activity in human pancreatic cancer
    Melisi, Davide
    Ossovskaya, Valeria
    Sherman, Barry M.
    Abbruzzese, James L.
    Chiao, Paul J.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3521S - 3522S
  • [34] First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers
    Yap, T. A.
    Boss, D. S.
    Fong, P. C.
    Roelvink, M.
    Tutt, A.
    Carmichael, J.
    O'Connor, M. J.
    Kaye, S. B.
    Schellens, J. H.
    de Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Phase 0 pharmacodynamic study of poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with refractory solid tumors and lymphomas: Immunohistochemistry results
    Yang, S. X.
    Kummar, S.
    Rubinstein, L.
    Gutierrez, M.
    Murgo, A. J.
    Parchment, R. E.
    Nguyen, D.
    Chen, A. P.
    Tomaszewski, J. E.
    Doroshow, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors
    Mingxiang Liao
    Simon Watkins
    Eileen Nash
    Jeff Isaacson
    Jeff Etter
    Jeri Beltman
    Rong Fan
    Li Shen
    Abdul Mutlib
    Vendel Kemeny
    Zsuzsanna Pápai
    Pascal van Tilburg
    Jim J. Xiao
    Investigational New Drugs, 2020, 38 : 765 - 775
  • [37] Discovery of bioactive small-molecule inhibitor of poly ADP-ribose polymerase: Implications for energy-deficient cells
    Altmann, Stephen M.
    Muryshev, Andrey
    Fossale, Elisa
    Maxwell, Michele M.
    Norflus, Francine N.
    Fox, Jonathan
    Hersch, Steven M.
    Young, Anne B.
    MacDonald, Marcy E.
    Abagyan, Ruben
    Kazantsev, Aleksey G.
    CHEMISTRY & BIOLOGY, 2006, 13 (07): : 765 - 770
  • [38] Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors
    Liao, Mingxiang
    Watkins, Simon
    Nash, Eileen
    Isaacson, Jeff
    Etter, Jeff
    Beltman, Jeri
    Fan, Rong
    Shen, Li
    Mutlib, Abdul
    Kemeny, Vendel
    Papai, Zsuzsanna
    van Tilburg, Pascal
    Xiao, Jim J.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 765 - 775
  • [39] Inhibition of poly (ADP-ribose) polymerase (PARP) by ABT-888 in patients with advanced malignancies: Results of a phase 0 trial
    Kummar, S.
    Kinders, R.
    Gutierrez, M.
    Rubinstein, L.
    Parchment, R. E.
    Phillips, L. R.
    Low, J.
    Murgo, A. J.
    Tomaszewski, J. E.
    Doroshow, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide.
    Plummer, R
    Middleton, M
    Wilson, R
    Evans, J
    Jones, C
    Olson, A
    Boddy, A
    Curtin, N
    Kaufman, R
    Harris, A
    Johnston, P
    Newell, H
    Robson, L
    Dewji, R
    Calvert, H
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9099S - 9099S
12345